MX2009012453A - Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones. - Google Patents

Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones.

Info

Publication number
MX2009012453A
MX2009012453A MX2009012453A MX2009012453A MX2009012453A MX 2009012453 A MX2009012453 A MX 2009012453A MX 2009012453 A MX2009012453 A MX 2009012453A MX 2009012453 A MX2009012453 A MX 2009012453A MX 2009012453 A MX2009012453 A MX 2009012453A
Authority
MX
Mexico
Prior art keywords
compositions
pal
lyase
methods
phenylalanine ammonia
Prior art date
Application number
MX2009012453A
Other languages
English (en)
Spanish (es)
Inventor
Paul A Fitzpatrick
Emil D Kakkis
Michel C Vellard
Daniel J Wendt
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009012453(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2009012453A publication Critical patent/MX2009012453A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2009012453A 2007-05-25 2008-05-23 Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones. MX2009012453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
PCT/US2008/006661 WO2008153776A1 (en) 2007-05-25 2008-05-23 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Publications (1)

Publication Number Publication Date
MX2009012453A true MX2009012453A (es) 2010-01-25

Family

ID=39868905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012453A MX2009012453A (es) 2007-05-25 2008-05-23 Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones.

Country Status (29)

Country Link
US (1) US7534595B2 (enExample)
EP (2) EP2152868B1 (enExample)
JP (1) JP5670183B2 (enExample)
KR (2) KR101603796B1 (enExample)
CN (1) CN101842482B (enExample)
AR (2) AR066716A1 (enExample)
AU (1) AU2008263190B2 (enExample)
BR (1) BRPI0811267B8 (enExample)
CA (1) CA2687450C (enExample)
CL (1) CL2008001497A1 (enExample)
CY (2) CY1116894T1 (enExample)
DK (1) DK2152868T3 (enExample)
EA (1) EA018443B1 (enExample)
ES (1) ES2551315T3 (enExample)
HR (1) HRP20151268T1 (enExample)
HU (2) HUE025784T2 (enExample)
IL (1) IL202132A (enExample)
LT (1) LTC2152868I2 (enExample)
LU (1) LUC00133I2 (enExample)
MX (1) MX2009012453A (enExample)
MY (1) MY151413A (enExample)
NL (1) NL301011I2 (enExample)
NO (1) NO2019037I1 (enExample)
PE (1) PE20090315A1 (enExample)
PL (1) PL2152868T3 (enExample)
PT (1) PT2152868E (enExample)
SI (1) SI2152868T1 (enExample)
TW (1) TWI418633B (enExample)
WO (1) WO2008153776A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP2531209B1 (en) 2010-02-04 2016-04-20 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
CA2880620A1 (en) * 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
SG11201508598YA (en) * 2013-04-18 2015-11-27 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス, インコーポレイテッド 合成膜−レシーバー複合体
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
DK3145536T3 (da) 2014-04-16 2022-01-03 Codexis Inc Modificeret tyrosinammoniaklyase
KR102438885B1 (ko) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法(一)
IL263801B2 (en) 2016-07-26 2024-01-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
JP7024951B2 (ja) * 2016-08-30 2022-02-24 三菱ケミカル株式会社 変異型酵素の製造方法及び変異型アルコールアシルトランスフェラーゼ
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
NZ755628A (en) * 2017-02-13 2023-09-29 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) * 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
CA3105916A1 (en) * 2018-07-12 2020-01-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11473077B2 (en) 2018-12-14 2022-10-18 Codexis, Inc. Engineered tyrosine ammonia lyase
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
US11987823B2 (en) 2019-08-30 2024-05-21 Societe Des Produits Nestle S.A. Engineered lipase variants
WO2021127457A1 (en) 2019-12-20 2021-06-24 Codexis, Inc. Engineered acid alpha-glucosidase variants
CA3168922A1 (en) 2020-02-04 2021-08-12 Codexis, Inc. Engineered leucine decarboxylases
US20230183712A1 (en) * 2020-02-19 2023-06-15 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療
JP2023539632A (ja) 2020-08-28 2023-09-15 コデクシス, インコーポレイテッド 操作されたプロテアーゼバリアント
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
US11918633B2 (en) 2021-05-19 2024-03-05 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
AU2022279241A1 (en) 2021-05-21 2023-11-30 Codexis, Inc. Engineered methionine gamma lyase variants
US20250000957A1 (en) * 2021-09-16 2025-01-02 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
PT668933E (pt) 1992-11-19 2003-02-28 Anticancer Inc Utilizacao de metioninase como agente anti-tumor em qimioterapia anti-metionina
ATE361984T1 (de) 1992-12-04 2007-06-15 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (enExample) 1993-06-25 1993-06-25 Novo Nordisk As
EP0776218A2 (en) * 1994-03-15 1997-06-04 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
DE851925T1 (de) 1995-09-21 2003-08-14 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
CA2315944A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
CA2328614C (en) 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
DE60021760T2 (de) * 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
WO2002008293A2 (en) * 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
AU2001294774A1 (en) * 2000-09-26 2002-04-08 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
WO2003072743A2 (en) 2002-02-26 2003-09-04 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
RU2324704C2 (ru) * 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
EP1576127A4 (en) 2002-11-14 2006-10-25 Scripps Research Inst CRYSTAL FORM OF FATTY ACID AMINE HYDROLASE (FAAH)
EP1636266A2 (en) * 2003-06-11 2006-03-22 Wyeth a Corporation of the State of Delaware Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
LUC00133I2 (enExample) 2020-07-16
LTPA2019517I1 (lt) 2019-10-25
EP2657335A1 (en) 2013-10-30
SI2152868T1 (sl) 2015-12-31
LTC2152868I2 (lt) 2020-09-25
EP2152868B1 (en) 2015-09-02
MY151413A (en) 2014-05-30
IL202132A0 (en) 2010-06-16
EA018443B1 (ru) 2013-08-30
HRP20151268T1 (hr) 2015-12-18
WO2008153776A8 (en) 2009-07-30
WO2008153776A1 (en) 2008-12-18
TWI418633B (zh) 2013-12-11
AU2008263190B2 (en) 2014-04-17
CY2019039I1 (el) 2020-05-29
HUE025784T2 (en) 2016-05-30
JP2010529835A (ja) 2010-09-02
EA200970980A1 (ru) 2010-04-30
AR110834A2 (es) 2019-05-08
KR20150038753A (ko) 2015-04-08
TW200902052A (en) 2009-01-16
US7534595B2 (en) 2009-05-19
LUC00133I1 (enExample) 2019-10-16
CA2687450A1 (en) 2008-12-18
CY1116894T1 (el) 2017-04-05
BRPI0811267B1 (pt) 2020-11-10
CL2008001497A1 (es) 2009-01-09
ES2551315T3 (es) 2015-11-18
AR066716A1 (es) 2009-09-09
BRPI0811267B8 (pt) 2021-05-25
IL202132A (en) 2017-06-29
PL2152868T3 (pl) 2016-01-29
JP5670183B2 (ja) 2015-02-18
CN101842482A (zh) 2010-09-22
KR101603796B1 (ko) 2016-03-17
HK1135141A1 (zh) 2010-05-28
NO2019037I1 (no) 2019-10-16
CY2019039I2 (el) 2020-05-29
NL301011I2 (nl) 2020-05-13
BRPI0811267A2 (pt) 2014-10-07
CN101842482B (zh) 2014-10-22
US20080008695A1 (en) 2008-01-10
EP2152868A1 (en) 2010-02-17
KR20100024437A (ko) 2010-03-05
NL301011I1 (nl) 2019-10-16
CA2687450C (en) 2019-03-26
PT2152868E (pt) 2015-11-13
PE20090315A1 (es) 2009-03-19
AU2008263190A1 (en) 2008-12-18
HUS1900049I1 (hu) 2019-11-28
DK2152868T3 (en) 2015-11-16

Similar Documents

Publication Publication Date Title
MX2009012453A (es) Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones.
MX2009012261A (es) Composiciones de fenilalanina amoniaco-liasa procariota y metodos para tratar cancer utilizando composiciones de las mismas.
CA2782444C (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
MX2009001203A (es) Muteinas de lipocalina lacrimosa y metodos para obtener las mismas.
EP3708581A3 (en) A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
WO2008075371A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
TW200738741A (en) Antiviral compounds
TW200738742A (en) Antiviral compounds
IN2012DN00721A (enExample)
MX2009013830A (es) Compuestos antivirales.
MX2009013827A (es) Compuestos antivirales.
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
IL190551A0 (en) Novel process for the preparation of acid chlorides
NZ703093A (en) Purification of iduronate-2-sulfatase
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
IN2012DN00639A (enExample)
CA2710814C (en) Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation
AU2016219650A1 (en) Compositions and methods for extended therapy with aminopyridines
JO2581B1 (en) Aryl sulfonomides replaced
MX2010010115A (es) Peptidos muy puenteados a partir de actinomadura namibiensis.
MX2007010143A (es) Formas cristalinas de intermedio de linezolid.
ZA200809686B (en) Lysobactin amindes
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
HK1136499A (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
SI1732886T1 (sl) Polimorfi terc butil estra atorvastatina in uporaba kot intermediati za pripravo atorvastatina

Legal Events

Date Code Title Description
FG Grant or registration